Perosphere, Daiichi Sankyo to test antidote to edoxaban

04/26/2013 | Pharmaceutical Business Review Online

Perosphere and Daiichi Sankyo have agreed to work together on a clinical trial that will assess the efficacy and safety of PER977, a drug being designed to reverse the anticoagulant effect of edoxaban, a factor Xa inhibitor. In preclinical testing, PER977 attached to heparins and factor Xa and IIa inhibitors but not to blood proteins.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC